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Abstract
Background: Morphine and its derivatives are key drugs in pain control. Despite its well-known
analgesic properties morphine at high concentrations may be proalgesic. Particularly, short-lasting
painful sensations have been reported upon dermal application of morphine. To study a possible
involvement of TRP receptors in the pro-nociceptive effects of morphine (0.3 – 10 mM), two
models of nociception were employed using C57BL/6 mice and genetically related TRPV1 and
TRPA1 knockout animals, which were crossed and generated double knockouts. Hindpaw skin
flaps were used to investigate the release of calcitonin gene-related peptide indicative of
nociceptive activation.
Results: Morphine induced release of calcitonin gene-related peptide and sensitized the release
evoked by heat or the TRPA1 agonist acrolein. Morphine activated HEK293t cells transfected with
TRPV1 or TRPA1. Activation of C57BL/6 mouse dorsal root ganglion neurons in culture was
investigated with calcium imaging. Morphine induced a dose-dependent rise in intracellular calcium
in neurons from wild-type animals. In neurons from TRPV1 and TRPA1 knockout animals activation
by morphine was markedly reduced, in the TRPV1/A1 double knockout animals this morphine
effect was abrogated. Naloxone induced an increase in calcium levels similar to morphine. The
responses to both morphine and naloxone were sensitized by bradykinin.
Conclusion: Nociceptor activation and sensitization by morphine is conveyed by TRPV1 and
TRPA1.
Background
After many thousands of years of therapeutic opium use,
in 1806 the German pharmacist Sertuerner published the
discovery of the main pharmacological compound of
opium, which he later called morphine [1]. From this
time morphine and its derivatives, which form the class of
opioids, became the main therapeutic option for the treat-
ment of moderate to severe pain. The analgesia as well as
most side effects are caused by interaction with the opioid
receptors, especially the mu-receptors.
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including addiction, sedation, constipation and nausea
[2]. Besides their well-known antinociceptive actions, opi-
oids can cause hyperalgesia by an unknown, opioid recep-
tor-independent mechanism [3,4]. This present study was
initiated by the clinical observation that in patients suffer-
ing from radiodermatitis, which could not be controlled
by systemic morphine, high doses of a custom-made opi-
oid gel applied topically to the skin can elicit severe burn-
ing pain for a few seconds (Clinical research group
KFO130, Erlangen, Germany). The isotonic gel prepared
by the university's pharmacy contains 2.67 mM (0.1%)
morphine and has a neutral pH. Case reports have previ-
ously reported hyperalgesia after application of high
doses of morphine [5,6]. At lower concentrations mor-
phine only causes pruritus, which might be explained by
mast cell degranulation [7].
The transient receptor potential channel TRPV1 (formerly
VR1) receptor is found in small to medium diameter dor-
sal root, trigeminal and nodose ganglia primary afferent
neurons which sense potentially damaging stimuli such as
capsaicin, heat and low pH [8,9]. For TPRV1 more pun-
gent activating compounds have been reported than for
any other TRPV channel. Another TRP channel, TRPA1
(formerly ANKTM1) equips neurons with a sensitivity for
mustard oil and many diverse pungent chemical stimuli
[10]. Among these compounds are electrophilic com-
pounds such as allyl isothiocyanate, acrolein, formalin,
15-deoxy-Δ12,14-prostaglandin J2, nitric oxide, hydrogen
peroxide as well as the inflammatory mediator bradykinin
[11]. TRPA1 and TRPV1 are the principal detectors for
painful chemical stimuli. The aim of this study was to
investigate whether the painful sensations evoked by mor-
phine are mediated by these two receptors. Two models of
nociceptive activation were employed using mice lacking
TRPV1, TRPA1 or both these receptors.
Results
Morphine activates hTRPV1 and TRPA1 expressed in 
HEK293t
In HEK293t cells transfected with hTRPV1 application of
10 mM morphine evoked an inward current, 300 μM cap-
saicin was applied as a control thereafter (n = 10, sample
recording in Fig. 1). In HEK293t cells transfected with
mTRPA1 10 mM morphine evoked inward currents that
appeared to rapidly inactivate during continued super-
fusion (n = 10). However, upon offset and washout of
morphine regularly large tail currents occurred that
revealed the sustained activation of TRPA1 and a slow
deactivation. Mustard oil (30 μM) was applied as a con-
trol thereafter.
Morphine elicits calcium transients in DRG neurons
A total of 106 dorsal root ganglion (DRG) neurons were
exposed to 10 mM morphine for 40 s, 30 μM acrolein for
30 s, 1 μM capsaicin for 5 s and 60 mM potassium for 30
s with an interval of 240 s between applications. Response
rates to morphine were 22%, to acrolein 45% and to cap-
saicin 58%. Morphine responses in neurons activated by
capsaicin but not by acrolein and in neurons activated by
acrolein but not capsaicin were larger than in neurons
which did not respond to either capsaicin or acrolein (p =
0.024 and p = 0.027, t-test independent samples).
Responses to morphine grouped by the sensitivity to cap-
saicin and acrolein are presented in Fig. 2a. Morphine (10
mM) was applied three times for 40 s. The second appli-
cation of morphine in the presence of BCTC (10 μM) and
HC030031 (50 μM) did not elicit a calcium increase
(both p < 0.001 compared to the initial and the third mor-
phine application, n = 62, Wilcoxon, Fig. 2b).
Increasing concentrations of morphine (0.1 – 10 mM)
were consecutively applied for 40 s, separated by 240 s
washout intervals. From C57BL/6 animals 134 DRG neu-
rons were tested. Morphine at 3 mM and 10 mM evoked a
concentration-dependent transient rise in intracellular
calcium (ANOVA, F(4,532) = 16.9, p = 0.005 and p < 0.001,
Morphine activates TRPV1 and TRPA1 expressed in HEK cellsFigure 1
Morphine activates TRPV1 and TRPA1 expressed in 
HEK cells. HEK cells transfected with cDNA for hTRPV1 
and mTRPA1 were exposed to 10 mM morphine. The upper 
traces show an inward current in a cell transfected by 
hTRPV1 and GFP, evoked by 10 mM morphine and by 300 
nM capsaicin, both applied for a period of 10 s. The lower 
traces show an inward current in a cell transfected by 
mTRPA1 and GFP, evoked by 10 mM morphine and by 30 
μM mustard oil, both applied for a period of 40 s. Cells were 
exposed to 1 μM m-3M3FBS before application of morphine 
and between applications.Page 2 of 11
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Morphine at 10 mM reached 32% of the 60 mM potas-
sium-induced calcium influx.
This protocol was repeated in neurons from TRPV1-/- (n =
112), TRPA1-/- (n = 125) as well as from TRPV1-/- TRPA1-/
- animals (n = 135). Compared to neurons from C57BL/6
mice, the increases in calcium levels evoked by 10 mM
morphine were smaller in animals lacking TRPV1 or
TRPA1 and almost absent in double knockouts (ANOVA,
F(9,1485) = 7.0; TRPV1-/-: 51%, p = 0.008; TRPA1-/-: 34%, p
= 0.005; TRPV1-/- TRPA1-/-: 2%, p < 0.001; % of AUC in
C57BL/6, HSD post-hoc tests). Compared to baseline, the
small morphine-induced increases of intracellular cal-
cium were still significant in neurons from TRPV1-/- (p <
0.001, ANOVA, F(4,444) = 13.0) and TRPA1-/- (p < 0.001,
ANOVA, F(4,468) = 24.6), but not so in neurons from
TRPV1-/- TRPA1-/- animals (p = 0.10, ANOVA, F(4,536) =
2.0). Due to the limited solubility of morphine at pH 7.4,
no higher concentrations than 10 mM could be tested.
Neurons activated by morphine were 20.5 ± 0.9 μm in
diameter, smaller than the average of 23.0 ± 0.5 μm (p =
0.041, U-test).
Sensitization by bradykinin and effect of naloxone
The inflammatory mediator bradykinin is known to acti-
vate nociceptive neurons in higher concentrations but in
lower concentrations to sensitize TRPV1 and TRPA1. To
determine whether calcium increases evoked by 10 mM
morphine are increased by bradykinin at a concentration
below activation, we applied the second of four consecu-
tive morphine applications in the presence of 5 μM brady-
kinin (Fig. 4). Bradykinin was applied 40 seconds before
the morphine stimulus and did not elicit a calcium
response (n = 111). Among the 22.5% of DRG neurons
responding to morphine, bradykinin increased the mor-
phine-stimulated calcium influx to 249% (ANOVA,
F(3,330) = 5.1, p= 0.002, HSD post-hoc test), the subse-
quent two morphine responses were not different com-
pared to the first one (p = 0.33 and p = 0.87, HSD post-
hoc tests). This protocol was repeated with morphine
replaced by naloxone, which is structurally similar but has
no intrinsic activity on opioid receptors. The activation by
naloxone was also concentration-dependent (n = 10, data
not shown). Bradykinin reversibly increased the
naloxone-stimulated calcium increase to 165% of the first
response (ANOVA, F(3,66) = 5.0, p = 0.025, HSD-post hoc
test).
Morphine-induced CGRP release from hindpaw skin
In order to reappraise these findings in intact innervated
tissue, we investigated the stimulated CGRP release from
nerve endings in isolated hind paw skin of C57BL/6 mice.
In a first series of experiments (n = 8) we assessed the
response to application of 10 mM morphine diluted in
SIF (Fig. 5). The basal CGRP concentration in the first
incubation period (SIF) was 2 ± 1 pg/ml. When the skin
flaps were transferred to the test tube containing 10 mM
morphine, the CGRP release increased to 20 ± 5 pg/ml (p
= 0.012, Wilcoxon). Final exposure to 60 mM KCl resulted
in a CGRP release of 54 ± 11 pg/ml.
Morphine sensitizes CGRP release induced by acrolein and 
heat
A separate series of experiments was performed to test the
hypothesis that morphine concentrations without a direct
effect on CGRP release may sensitize cutaneous afferents
to noxious stimuli activating TRPV1 or TRPA1. CGRP
release in the presence of 310 μM morphine was not dif-
ferent from the basal release (Fig. 6). The selective agonist
Morphine activates DRG neurons responsive to capsaicin and acroleinFigure 2
Morphine activates DRG neurons responsive to cap-
saicin and acrolein. Upper panel. Morphine, acrolein and 
capsaicin were applied to 106 wildtype DRG neurons. The 
average calcium increase evoked by morphine 10 mM is com-
pared in neurons grouped by sensitivity to capsaicin and 
acrolein. Neurons responsive to capsaicin, acrolein or both 
showed a larger calcium signal response to morphine than 
neurons not responsive to both capsaicin and acrolein. 
Lower panel. Wildtype DRG neurons were exposed to three 
repetitive applications of 10 mM morphine (n = 62). In the 
presence of 10 μM BCTC and 50 μM HC030031, morphine 
evoked no significant increase in intracellular calcium.Page 3 of 11
(page number not for citation purposes)
Molecular Pain 2009, 5:17 http://www.molecularpain.com/content/5/1/17
Page 4 of 11
(page number not for citation purposes)
Morphine dose-dependently activates DRG neurons via TRPA1 and TRPV1 receptors causing increases in intracellular calciumFigure 3
Morphine dose-dependently activates DRG neurons via TRPA1 and TRPV1 receptors causing increases in 
intracellular calcium. Morphine application periods lasting 40 s are indicated by bars. The upper four panels show the fluo-
rescence ratios of the four tested genotypes, presented as mean ± SEM of all neurons (number of neurons, C57Bl/6: 134, 
TRPV1-/-: 112, TRPA1-/-: 125 and TRPV1-/- TRPA1-/-: 135). All neurons responded to 60 mM KCl at the end of the experiment 
(not shown). The stacked histogram inset in the uppermost panel shows that preferentially small size DRG neurons respond to 
morphine (black bars, x: cell diameter in μm, y: number of cells). The bottom panel summarizes the dose-dependent activation. 
The integral of the fluorescence ratio during the application period was normalized to the response elicited by 60 mM KCl.
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Bradykinin sensitizes activation of neurons by morphine and naloxoneFigure 4
Bradykinin sensitizes activation of neurons by morphine and naloxone. Repetitive activation of DRG neurons elicited 
by 40 s applications of morphine and naloxone. Bradykinin reversibly sensitized calcium influx evoked by both morphine (n = 
111) and naloxone (n = 91) but did not evoke a response when applied alone 40 s prior to morphine or naloxone. Bars indicate 
application periods; data are presented as mean ± SEM. The lower panel summarizes the calcium increases normalized to indi-
vidual responses to 60 mM KCl. *p < 0.05
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end of the concentration-response relationship; in pres-
ence of 310 μM morphine acrolein caused markedly
greater increases in CGRP release (p = 0.028, n = 6, Wil-
coxon). A similar series of experiments was performed for
noxious heat stimulation using SIF at 47°C; heat-induced
cutaneous CGRP release depends partly on TRPV1 as a
transducer. The exposure to 310 μM morphine caused no
rise in CGRP release (Fig. 7), but slightly sensitized the
release evoked by heat stimulation (p = 0.018, n = 7, Wil-
coxon, compared to 47°C on the control side).
Discussion
Morphine and naloxone at high concentrations were
found to activate cultured primary afferent neurons in a
concentration-dependent manner demonstrated by
inward currents and calcium transients. TRPV1 and
TRPA1 but not opioid receptors conveyed this activation.
The inflammatory mediator bradykinin increased the
neuronal sensitivity to morphine and naloxone. Mor-
phine concentrations below the activation threshold sen-
sitized TRPV1 and TRPA1 in native cutaneous nerve
endings releasing CGRP.
Clinical observation
The present study was initiated by the observation of pain-
ful sensations caused by topical application of a 2.67 mM
morphine gel to inflamed skin following radiation ther-
apy, as reported in the interdisciplinary pain research
group (KFO 130). In these patients, the topical morphine
formulation (prepared by the pharmacy unit of the uni-
versity) was preferred because systemic opiates could not
be applied systemically due to unwanted side effects. The
painful sensations were reported to last only for a few sec-
onds but exceeded seven on a ten-point rating scale. The
time course of the pain was similar to that reported after
injection of lidocaine, which has recently been shown to
activate nociceptive afferents via TRPV1 and TRPA1 recep-
tors before sodium channel blockade leads to local
anesthesia [12]. Similarly for morphine, an inhibition of
sodium channels has been described [13-15], masking by
conduction block the sustained activation. Sodium chan-
nel block also occurs with naloxone [16], shedding
doubts on alleged naloxone reversal of peripheral opioid
effects.
The radiation dermatitis involves a tailored therapy; topi-
cal application of morphine is not the primary choice but
rather an uncommon option. This might explain why sys-
tematic studies are not available. Common symptomatic
therapy of radiation dermatitis is based on topical wound
care predominantly involving moisturizers. There is no
uniequivocal evidence for a causal therapy, including the
topical application of ascorbic acid, corticosteroids or cal-
cineurin inhibitors; opioids have not been investigated so
far [17].
Receptors mediating opioid effects
There is evidence for peripheral opioid receptor effects
[18-20]. The expression profile of opioid receptors on pri-
Morphine elicits release of CGRPFigure 5
Morphine elicits release of CGRP. Morphine (10 mM) 
applied for 5 minutes reversibly stimulates the release of 
CGRP from the isolated hindpaw skin of mice (n = 8). Syn-
thetic interstitial fluid containing 60 mM KCl was applied for 
comparison. *p < 0.05
Morphine sensitizes CGRP-release stimulated by acroleinFigure 6
Morphine sensitizes CGRP-release stimulated by 
acrolein. Release of CGRP from isolated hindpaw skin of 
mice was stimulated by 100 μM acrolein applied for 5 min 
(open symbols). The contralateral hindpaw skin of every ani-
mal was exposed to acrolein in the presence of 310 μM mor-
phine (closed symbols) which sensitized the release of CGRP 
evoked by acrolein (n = 6). *p < 0.05Page 6 of 11
(page number not for citation purposes)
Molecular Pain 2009, 5:17 http://www.molecularpain.com/content/5/1/17mary afferent neurons corresponds to the nociceptor pop-
ulation [21,22]. Peripheral application of opioid receptor
agonists (below 100 μM) or antagonists demonstrated
their local efficacy but the relative contribution of periph-
eral opioid receptors after systemic opioid administration
is still unclear [23].
In animal experiments involving peripheral opioid injec-
tions or topical morphine applications, pain-related
behavior has not been reported [24-26]. However, it
seems likely that in these studies morphine concentra-
tions at the nerve endings were below the activation
threshold of nociceptors. A behavioural correlate for the
activation of TRPV1 and TRPA1 by morphine injection is
not easily detected since the immediate pain of skin punc-
ture is closely followed by the nerve conduction block.
The only previously reported application of a high con-
centration of morphine in a well-controlled setup pro-
duced nociceptor activation, as observed in the present
study. In this preparation, the superior spermatic nerve of
dogs in vitro, morphine applied by superfusion at 1 – 310
μM generated action potentials in slowly conducting affer-
ents; the activation was concentration-dependent and the
combination of bradykinin and morphine resulted in sen-
sitization [27]. In the present study the applied concentra-
tions were higher, and 310 μM morphine caused
sensitization but no overt activation. A higher expression
of TRPA1 and TRPV1 in visceral afferents [28,29] might
Morphine sensitizes CGRP-release stimulated by noxious heatFigure 7
Morphine sensitizes CGRP-release stimulated by noxious heat. Release of CGRP from isolated hindpaw skin of mice 
stimulated by noxious heat of 47°C applied for 5 min (open symbols). The contralateral hindpaw skin flap of every animal was 
exposed to 47°C in the presence of 310 μM morphine (closed symbols) which slightly facilitated the release of CGRP stimu-
lated by heat (n = 7). The inset shows the results with and without morphine for every animal. *p < 0.05.Page 7 of 11
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required for activation of testicular nociceptors.
For the reported painful sensations in patients or the acti-
vation of primary afferents, a G-protein coupled opioid
receptor effect seems unlikely in view of the action of the
opioid antagonist naloxone. Since TRPV1 and TRPA1 are
the principal detectors for painful chemical compounds,
they were the primary targets of the investigation. Consid-
ering pharmacological results and activation of neurons
from knockout animals, both TRP receptors contributed
approximately equal to the activation of DRG neurons
caused by morphine. Only the knockout of both receptors
eliminated the responsiveness.
The observed morphine-induced increase in calcium lev-
els is only a fraction of that elicited by KCl. This might
explain why a lower percentage of neurons was activated
by morphine in comparison to acrolein and capsaicin.
Inhibition of calcium conductance by morphine is a pos-
sible explanation. In fact, morphine and the mu-agonist
DAGO (Tyr-D-Ala-Gly-MePhe-Gly-ol) reduce the conduc-
tivity of voltage gated calcium channels [30,31], which
may be activated secondary to neuronal depolarization
via TRPV1 and TRPA1. For TRPA1, both morphine and
mustard oil seem to inhibit ion flux through TRPA1, a tail
current was observed when the application was stopped.
The apparent desensitization is likely due to an additional
pore blocking effect that morphine at high concentration
may exert on TRPA1. Mustard oil, the index agonist of
TRPA1, also induced, yet smaller, tail currents followed by
slow deactivation. Together with the very slow activation
this may suggest that also mustard oil exerts a double
action on TRPA1, activation of the receptor-channel and
partial pore block.
Stimulated CGRP release
The neuropeptide calcitonin gene related peptide CGRP is
expressed by a large subset of predominantly nociceptive
primary afferent neurons and released upon activation of
these neurons. The measurement of released CGRP is
therefore widely used as an index for the activation of
nociceptors. CGRP is expressed in a large proportion of
neurons positive for TRPV1 or TRPA1, therefore the
release of CGRP is a favorable readout for the activation of
these neurons [32,33]. High concentrations of morphine
reversibly stimulated the release of CGRP from the iso-
lated skin. Furthermore, concentrations below the thresh-
old of activation sensitized the CGRP release evoked by
noxious heat and acrolein, activators of TRPV1 and TRPA1
receptors, respectively.
In inflamed skin inflammatory mediators and their recep-
tors are frequently overexpressed [34,35], among them
particularly bradykinin and its receptors [36]. Bradykinin
sensitizes TRPV1 [37] and TRPA1 [38]. Therefore it was
not surprising that morphine responses were sensitized by
bradykinin. Sensitization to morphine by bradykinin and
a reduced barrier function may explain the particular
painfulness of the treated skin areas in radiodermatitis
patients.
Conclusion
Morphine, at doses rarely used for pain therapy, is a nox-
ious stimulus activating both TRPV1 and TRPA1 receptors.
Morphine-induced calcium increase, indicative for nocic-
eptive activation, was reduced in DRG neurons from
TRPV1 and TRPA1 knockout animals. Moreover, TRPV1/
A1 double knockout mice were used for the first time to
demonstrate by the lack of activation that both receptors
together fully account for the nociceptive sensitivity to
morphine. We suggest that also the sensitivity for several
other algogenic compounds that still elicit pain and acti-
vate neurons in the single knockouts will be lost in these
double knockout animals.
Methods
Animals
Animal care and treatment were in accordance with the
guidelines of the International Association for the Study
of Pain [39]. Adult C57Bl/6, TRPV1-/- and TRPA1-/- as well
as TRPV1-/-TRPA1-/- double knockout mice were used.
Breeding pairs of TRPV1 and TRPA1 knockout mice were
obtained from Dr. John Davis [40] and Dr. David Corey
[41] and backcrossed to C57BL/6. Double knockout ani-
mals were generated in our animal facility by cross-mating
knockouts of both strains. All animals were genotyped by
the previously reported primers.
Cell culture
Animals were killed in pure CO2 atmosphere. Dorsal root
ganglia of all lumbar and the first two thoracic segments
of the spinal column were excised and transferred in Dul-
becco's modified Eagle's medium (DMEM, Invitrogen,
Carlsbad, USA) solution containing 50 μg/ml gentamicin
(Sigma). The ganglia were treated with 1 mg/ml colla-
genase and 0.1 mg/ml protease for 30 minutes (both from
Sigma) in TNB 100 solution supplemented by TNB 100
lipid-protein-complex, 100 μg/ml streptomycin and pen-
icillin (all from Biochrom, Berlin, Germany) and 200 μg/
ml glutamine (Invitrogen, Carlsbad, USA) for 20 minutes
at 37°C. After three wash steps, the suspension was tritu-
rated in TNB solution using a fire-polished silicone-coated
Pasteur pipette. The cells were plated on poly-D-lysine-
coated (Sigma) cover slips and cultured in TNB medium
overnight at 37°C in a humidified 5% CO2 atmosphere.
Patch Clamp Recordings
HEK293t cells were transfected with plasmids of hTRPV1
(John Davis) or mTRPA1 (Ardem Patapoutian) along withPage 8 of 11
(page number not for citation purposes)
Molecular Pain 2009, 5:17 http://www.molecularpain.com/content/5/1/17GFP as reporter plasmid using Polyfect (Qiagen, Hilden,
Germany) according to the manufacturer's protocol. After
incubation for one day, the cells were replated in 35 mm
culture dishes and used for experiments within 1–2 days.
GFP-expressing cells were identified by fluorescence.
Recording electrodes were pulled from borosilicate glass
tubes (GB150T-8P, Science Products, Hofheim, Germany)
to give a resistance of 3.5 – 5.0 MΩ (P97, Sutter, Novato,
CA). The external solution contained (in mM) 140 NaCl,
4 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, 4 glucose, adjusted
to pH 7.4. The internal solution contained (in mM) 140
KCl, 1.6 MgCl2, 2 EGTA and 10 HEPES and was adjusted
to pH 7.4. Recordings were performed at room tempera-
ture and cells were held at -60 mV. Membrane currents
were acquired with an Axopatch 200B amplifier and
pClamp 10 software (Molecular Devices, Sunnyvale, CA).
Solutions were applied with a RSC-100 gravity-driven
solution changer (Bio-Logic, Claix, France). All cells were
first exposed to morphine, then to capsaicin or mustard
oil. TRPA1 was sensitized by PLC activator m-3M3FBS (1
μM, Sigma).
Calcium imaging
Cells were stained by 5 μM fura-2 AM and 0.02% pluronic
F-127 (both from Invitrogen) dissolved in the TNB
medium for about 30 min in the incubator, followed by a
short wash-out period to allow fura-2 AM ester hydrolysis.
The cover slips were placed in a custom-made chamber
and mounted on a Zeiss Axiovert inverse microscope with
a 40× NeoFluar objective. Cells were continuously super-
fused throughout the experiment with extracellular fluid
(in mM: NaCl 145, KCl 5, CaCl2 1.25, MgCl2 1, Glucose
10, Hepes 10) at a flow rate of approximately 0.3 ml/min
at room temperature. Cells were illuminated with a 75W
xenon arc lamp and a monochromator alternating
between 340 and 380 nm of wavelength (Photon Tech-
nology International, New Jersey, USA). Images were
acquired at 1 Hz with 200 μs exposure time using a CCD
camera, controlled by Image Master software (PTI, Bir-
mingham, USA). Fluorescence ratios were computed for
regions of interest adapted to the neurons. All experimen-
tal protocols were pre-programmed using a custom-made
software that controls the valves of a 7-channel gravity-
driven common-outlet superfusion system [42].
CGRP release
C57/Bl6 mice of either sex with an average weight of 20 g
(range 12–27 g) were used. The skin of both hind paws
distal to the knee was subcutaneously excised. The skin
flaps with an average weight of 105 mg (range 57–135
mg, n = 36) were fixed to acrylic rods by surgical threads
with the corium exposed. During this procedure the skin
flaps were constantly immersed in synthetic interstitial
fluid (SIF, in mM: NaCl 107.8, KCl 3.5, NaHCO3 26.2,
NaH2PO4 1.7, Na-gluconate 9.6, sucrose 7.6, glucose 5.6,
CaCl2 1.5 and MgSO4 0.7 [43] equilibrated with carbogen
(pH 7.4). The fixed skin flaps were placed in test tubes and
mounted in a shaking bath of 32°C. After washing for 30
minutes, each experiment was composed of four consecu-
tive 5 min incubation periods in test tubes filled with 0.8
ml SIF. In the first two periods basal CGRP release was
determined, during the third period the preparation was
chemically or thermally stimulated, the fourth period was
for the post-stimulation control. One separate protocol
provided two stimulations in incubation periods two and
four. The contralateral hind paw skin of each animal was
used as a matched-pairs control without conditioning
chemicals.
Enzyme-immuno assay for CGRP
Immediately after the incubation, 100 μl of the solution
were processed using a commercial CGRP enzyme
immune assay kit (SPIbio, France). The details of this
method were described previously [44]. The antibodies
used are directed against human α/β-CGRP but are 100%
cross-reactive against mouse and rat CGRP. The detection
level is about 2 pg/ml. Samples of SIF and all stimulation
solutions measured on the same enzyme immune assay
96-well plate served as controls.
Data analysis
The calcium influx elicited by a stimulus was quantified
by evaluating the area under the curve (AUC) of the appli-
cation period. Absolute increases in calcium concentra-
tions were calculated based on Rmin and Rmax [45].
Compared to the foregoing reference period a mean
increase of the intracellular calcium concentration of at
least 15 nM throughout the application period was con-
sidered as activation. At the end of all protocols a 10 s
stimulus of KCl 60 mM was applied as control and nor-
malization reference. Cell diameter was calculated as the
mean of two orthogonal axes. Repeated measurements
and independent groups in calcium imaging experiments
were compared by ANOVA and HSD post-hoc test. CGRP
release experiments were performed using both hindpaw
skin flaps of the same animal and compared using the
Wilcoxon matched pairs test. Statistical analysis was per-
formed using Statistica 7 (Tulsa, OK, USA), sigmoidal
dose-response curves were fitted by Origin 7.5 (North-
hampton, MA, USA). Data are presented as mean ± SEM;
p < 0.05 was considered significant.
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